TABLE 2.
Overview of (non)Significant Changes in Patient-reported Outcome Measures in Patients With Polycystic Liver Disease Undergoing Various Treatment Options Compared With Baseline
Black = Statistical difference, Dark grey = conflicting findings, Light grey = no statistical, difference, White = no data available.
GI indicates gastrointestinal questionnaire; mTOR, mammalian target of rapamycin; UDCA, ursodeoxycholic acid etc; V2R, vasopressin-2-receptor.